Targeted Therapeutics is estimated at 44.0% by Product Type in 2026, while Lung Cancer is projected at 28.0% and Next-Generation Sequencing at 38.0%. Adoption depends on timely biomarker results that can enter routine oncology decisions.
Oncology Precision Medicine Market Analysis By ApplicationOncology Precision Medicine Market Analysis By Cancer TypeOncology Precision Medicine Market Analysis By End UserOncology Precision Medicine Market Analysis By TechnologyOncology Precision Medicine Market Opportunity Matrix Growth Vs ValueOncology Precision Medicine Market Breakdown By Product Type, Cancer Type, And Region